График акции Immuneering Corporation
Расширенный график
Простой график
О компании
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Выручка |
0.0019 |
EBITDA |
-0.0073 |
Число акций ао |
0.02842 млрд |
P/S |
211.07 |
P/BV |
2.81 |
EV/EBITDA |
-0.3855 |
Цена ао |
2.39 |
ISIN |
US45254E1073 |
Сайт |
https://immuneering.com
|
Валюта |
usd |
IPO date |
2021-07-30 |
Sector |
Health Care |
Industry |
Biotechnology |
Валюта отчета |
usd |
Изменение цены за день: |
0% (2.31) |
Изменение цены за неделю: |
+5.48% (2.19) |
Изменение цены за месяц: |
+14.36% (2.02) |
Изменение цены за 3 месяца: |
+102.63% (1.14) |
Изменение цены за полгода: |
+28.33% (1.8) |
Изменение цены за год: |
-61.5% (6) |
Изменение цены за 3 года: |
-92.06% (29.11) |
Изменение цены с начала года: |
-64.62% (6.53) |
|
Недооценка
Название |
Значение |
Оценка |
P/S |
467155.72 |
1 |
P/BV |
2.35 |
6 |
P/E |
0 |
0 |
EV/EBITDA |
-2.73 |
0 |
Итого: |
|
3.5 |
|
Эффективность
Название |
Значение |
Оценка |
ROA, % |
-52.12 |
0 |
ROE, % |
-59.03 |
0 |
Итого: |
|
0 |
|
|
Дивиденды
Название |
Значение |
Оценка |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Итого: |
|
0 |
|
Долг
Название |
Значение |
Оценка |
Debt/EBITDA |
-0.0774 |
10 |
Итого: |
|
8.6 |
|
Импульс роста
Название |
Значение |
Оценка |
Доходность Revenue, % |
-99.98 |
0 |
Доходность Ebitda, % |
695.35 |
10 |
Доходность EPS, % |
100.27 |
10 |
Итого: |
|
8 |
|
Руководитель |
Должность |
Оплата |
Год рождения |
Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Co-Founder, President, CEO & Director |
935.09k |
1983 (41 год) |
Dr. Brett M. Hall Ph.D. |
Chief Scientific Officer |
905.41k |
1969 (55 лет) |
Ms. Mallory Morales CPA |
Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer |
N/A |
1984 (40 лет) |
Ms. Paula George CPA |
Director of Accounting & Operations and Assistant Corporate Controller |
N/A |
|
Mr. Michael D. Bookman J.D. |
Chief Legal Officer & Secretary |
N/A |
1987 (37 лет) |
Ms. Leah R. Neufeld |
Chief People Officer |
N/A |
1973 (51 год) |
Dr. Peter King Ph.D. |
Head of Discovery & VP |
N/A |
|
Dr. Praveen Nair Ph.D. |
Head of Translational Pharmacology & VP |
N/A |
|
Mr. Harold E. Brakewood |
Chief Business Officer |
579.77k |
1966 (58 лет) |
Mr. Robert J. Carpenter M.B.A., M.S. |
Co-Founder & Chair Emeritus |
75.36k |
1946 (78 лет) |